VELCADE® (bortezomib)

VELCADE Reimbursement Assistance Program

Welcome to the VELCADE Reimbursement Assistance Program (VRAP), where it’s our goal to help you get the treatment your doctor has prescribed, no matter your insurance or financial situation.

Multiple myeloma and relapsed mantle cell lymphoma often require expensive treatment regimens, so it is important to understand how your insurance coverage works. Understanding your insurance coverage will help you understand the out-of-pocket expenses for which you may be responsible.

VRAP is available to patients, physicians, and caregivers to provide assistance regarding reimbursement issues related to the use of VELCADE® (bortezomib) for Injection. The program is easily accessed by calling 1-866-VELCADE, option 2. Dedicated Case Managers are available from 8:00 am to 8:00 pm Eastern Standard Time (EST).

How VELCADE® (bortezomib) Works

page sponsored by VELCADE®

VELCADE is an important option for treating patients with multiple myeloma and patients with relapsed mantle cell lymphoma (MCL) because it gives you another way to fight your disease. VELCADE is a type of medicine called a proteasome (pro-tee-uh-zohm) inhibitor. It is the only proteasome inhibitor the FDA has approved.

What Are Proteasomes?

Proteasomes are protein complexes inside all human cells, both healthy and cancerous. They work by breaking down unneeded or damaged proteins in your cells. This normal process maintains a balance within the cell, allowing cells to live and grow.

What Is a Proteasome Inhibitor?

VELCADE is a proteasome inhibitor that temporarily blocks, or inhibits, proteasomes from breaking down proteins. This causes a buildup of proteins in the cell. When there are too many proteins in the cells, the cells stop growing and die.

Take a Closer Look at Proteasome Inhibition

Proteasomes are inside all human cells and break down proteins.

Proteasome inhibitors block the proteasome from working, causing a buildup of proteins in the cell.

This buildup of proteins can cause cells—including cancer cells—to die, as well as slow tumor growth.

Please click here To request a Patient Resource Kit for VELCADE® (bortezomib). This complimentary kit includes information about VELCADE for multiple myeloma or relapsed MCL along with tools to help you manage your disease.

VELCADE may be able to help treat your multiple myeloma or relapsed mantle cell lymphoma.

VELCADE is the first treatment approved by the FDA from a class of medicines called proteasome inhibitors. VELCADE is an effective treatment for patients with multiple myeloma and relapsed mantle cell lymphoma and is given intravenously as a 3- to 5-second injection. To date, more than 160,000 patients have been treated with VELCADE.* Learn how proteasome inhibitors work.

VELCADE can be used to treat many patients, including the elderly and those with kidney disease.

VELCADE should not be used in patients who are pregnant, planning to become pregnant or breastfeeding, as well as those who are allergic or hyper-sensitive to bortezomib, boron or mannitol, the ingredients VELCADE is made of.

You and your doctor will discuss your treatment options to decide if VELCADE is an option for you. Learn more about considering VELCADE.